RESUMO
BACKGROUND: The use of stress ulcer prophylaxis (SUP) has risen in recent years, even in patients without a clear indication for therapy. AIM: To evaluate the efficacy of an electronic medical record (EMR)-based alarm to improve appropriate SUP use in hospitalized patients. METHODS: We conducted an uncontrolled before-after study comparing SUP prescription in intensive care unit (ICU) patients and non-ICU patients, before and after the implementation of an EMR-based alarm that provided the correct indications for SUP. RESULTS: 1627 patients in the pre-intervention and 1513 patients in the post-intervention cohorts were included. The EMR-based alarm improved appropriate (49.6% vs. 66.6%, p<0.001) and reduced inappropriate SUP use (50.4% vs. 33.3%, p<0.001) in ICU patients only. These differences were related to the optimization of SUP in low risk patients. There was no difference in overt gastrointestinal bleeding between the two cohorts. Unjustified costs related to SUP were reduced by a third after EMR-based alarm use. CONCLUSIONS: The use of an EMR-based alarm improved appropriate and reduced inappropriate use of SUP in ICU patients. This benefit was limited to optimization in low risk patients and associated with a decrease in SUP costs.
Assuntos
Alarmes Clínicos , Registros Eletrônicos de Saúde , Prescrição Inadequada/prevenção & controle , Úlcera Péptica Hemorrágica/diagnóstico , Úlcera Péptica/prevenção & controle , Antiulcerosos/uso terapêutico , Comorbidade , Custos e Análise de Custo , Antagonistas dos Receptores H2 da Histamina/uso terapêutico , Humanos , Pacientes Internados , Unidades de Terapia Intensiva , Úlcera Péptica/tratamento farmacológico , Úlcera Péptica Hemorrágica/prevenção & controle , Inibidores da Bomba de Prótons/uso terapêutico , Respiração Artificial , Risco , Centros de Atenção TerciáriaRESUMO
Fabry disease is a rare inherited lysosomal storage disorder caused by the deficiency of the enzyme alpha-galactosidase A. There is uncertainty regarding the safety of enzyme replacement therapy during pregnancy. We describe the course and outcome of seven pregnancies in six patients with Fabry disease who continued or reinitiated enzyme replacement therapy during pregnancy. No adverse events, in both mothers and children, were observed.